MX2022003051A - Formulaciones para la administracion de farmacos. - Google Patents

Formulaciones para la administracion de farmacos.

Info

Publication number
MX2022003051A
MX2022003051A MX2022003051A MX2022003051A MX2022003051A MX 2022003051 A MX2022003051 A MX 2022003051A MX 2022003051 A MX2022003051 A MX 2022003051A MX 2022003051 A MX2022003051 A MX 2022003051A MX 2022003051 A MX2022003051 A MX 2022003051A
Authority
MX
Mexico
Prior art keywords
drug delivery
delivery formulations
risperidone
triblock
disorders
Prior art date
Application number
MX2022003051A
Other languages
English (en)
Spanish (es)
Inventor
Christophe Roberge
Anthony Rech
Eran Harary
Original Assignee
Medincell S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medincell S A filed Critical Medincell S A
Publication of MX2022003051A publication Critical patent/MX2022003051A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
MX2022003051A 2019-09-13 2020-09-11 Formulaciones para la administracion de farmacos. MX2022003051A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962900061P 2019-09-13 2019-09-13
PCT/IB2020/058474 WO2021048817A1 (en) 2019-09-13 2020-09-11 Drug delivery formulations

Publications (1)

Publication Number Publication Date
MX2022003051A true MX2022003051A (es) 2022-06-14

Family

ID=72521677

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003051A MX2022003051A (es) 2019-09-13 2020-09-11 Formulaciones para la administracion de farmacos.

Country Status (19)

Country Link
US (3) US12383493B2 (cg-RX-API-DMAC7.html)
EP (2) EP4706658A3 (cg-RX-API-DMAC7.html)
JP (2) JP7661312B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220062372A (cg-RX-API-DMAC7.html)
CN (1) CN114727946A (cg-RX-API-DMAC7.html)
AU (2) AU2020346455B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022004535A2 (cg-RX-API-DMAC7.html)
CA (1) CA3153793A1 (cg-RX-API-DMAC7.html)
DK (1) DK4027973T3 (cg-RX-API-DMAC7.html)
ES (1) ES3058225T3 (cg-RX-API-DMAC7.html)
FI (1) FI4027973T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251690T1 (cg-RX-API-DMAC7.html)
IL (1) IL291283A (cg-RX-API-DMAC7.html)
LT (1) LT4027973T (cg-RX-API-DMAC7.html)
MX (1) MX2022003051A (cg-RX-API-DMAC7.html)
PL (1) PL4027973T3 (cg-RX-API-DMAC7.html)
PT (1) PT4027973T (cg-RX-API-DMAC7.html)
SI (1) SI4027973T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021048817A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI4027973T1 (sl) * 2019-09-13 2026-02-27 Medincell S.A. Formulacije za dostavo zdravil
US20240148641A1 (en) * 2021-03-17 2024-05-09 Medincell S.A. Long Acting Injectable Formulation Comprising Risperidone and Biodegradable Polymers
WO2026013080A1 (en) 2024-07-08 2026-01-15 InnoCore Technologies Holding B.V. Pharmaceutical composition based on biodegradable polymers comprising polyoxazoline

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999007343A1 (en) * 1997-08-08 1999-02-18 University Of Utah Research Foundation Injectable biodegradable block copolymer gels for use in drug delivery
JP4223961B2 (ja) 2002-01-31 2009-02-12 Agcテクノグラス株式会社 霊長類胚性幹細胞の凍結保存方法
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
KR101707791B1 (ko) 2008-09-30 2017-02-17 엔도 파마슈티컬즈, 솔루션스 아이엔씨. 리스페리돈 전달용 이식형 장치
CN101584652B (zh) * 2009-06-19 2012-06-20 上海医药集团股份有限公司 利培酮缓释凝胶注射剂及其制备方法
MY165655A (en) * 2010-12-29 2018-04-18 Medincell Biodegradable drug delivery compositions
WO2013063125A1 (en) * 2011-10-24 2013-05-02 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions and methods of treatment thereof
KR102189442B1 (ko) * 2012-06-27 2020-12-11 메딘셀 에스.에이. 소수성 조성물용 생분해성 약물 전달
WO2014164754A1 (en) * 2013-03-11 2014-10-09 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
LT3655038T (lt) * 2017-07-17 2025-02-10 Medincell S.A. Farmacinė kompozicija
SI4027973T1 (sl) * 2019-09-13 2026-02-27 Medincell S.A. Formulacije za dostavo zdravil

Also Published As

Publication number Publication date
CA3153793A1 (en) 2021-03-18
AU2020346455A1 (en) 2022-03-31
JP2022548616A (ja) 2022-11-21
US20220331240A1 (en) 2022-10-20
JP7661312B2 (ja) 2025-04-14
BR112022004535A2 (pt) 2022-06-07
HRP20251690T1 (hr) 2026-02-13
US12128132B2 (en) 2024-10-29
IL291283A (en) 2022-05-01
ES3058225T3 (en) 2026-03-09
US12383493B2 (en) 2025-08-12
EP4706658A2 (en) 2026-03-11
CN114727946A (zh) 2022-07-08
US20250268817A1 (en) 2025-08-28
DK4027973T3 (da) 2026-01-12
PT4027973T (pt) 2026-01-05
AU2020346455B2 (en) 2025-07-03
FI4027973T3 (fi) 2026-01-14
PL4027973T3 (pl) 2026-03-09
SI4027973T1 (sl) 2026-02-27
LT4027973T (lt) 2026-01-26
WO2021048817A1 (en) 2021-03-18
EP4706658A3 (en) 2026-06-03
EP4027973B1 (en) 2025-11-05
US20240156722A1 (en) 2024-05-16
EP4027973A1 (en) 2022-07-20
JP2025106353A (ja) 2025-07-15
AU2025242078A1 (en) 2025-10-23
EP4027973B8 (en) 2025-12-17
KR20220062372A (ko) 2022-05-16

Similar Documents

Publication Publication Date Title
EP4272818A3 (en) Thrombolytic agent for the treatment of thromboembolism
PH12021551792A1 (en) Bi-ligand drug conjugate and use thereof
MX2021007970A (es) Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.
MY199903A (en) Combination therapy with controlled-release cnp agonists
LUC00011I1 (cg-RX-API-DMAC7.html)
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
WO2010123569A3 (en) Immunonanotherapeutics providing a th1-biased response
WO2014160155A3 (en) Implantable drug delivery compositions comprising non-polymeric sorption enhancers and methods of treatment thereof
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
BR112022004535A2 (pt) Formulações de entrega de fármaco
PH12019502651A1 (en) Use of vibegron to treat overactive bladder
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MY193963A (en) Composition for treating joint diseases and kit containing same
AU2018260628A1 (en) Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
ZA202003904B (en) Drug delivery system
MX2023010925A (es) Formulacion inyectable de accion prolongada que comprende risperidona y polimeros biodegradables.
NZ760033A (en) Methods to treat opioid use disorder
MY206505A (en) Therapeutic agent for glaucoma comprising fp agonist and -blocker
MX2023005398A (es) Formulaciones, metodos, kits y formas de dosificacion.
EA201590323A1 (ru) Способ введения активных веществ в головной мозг
SA522432821B1 (ar) توليفة من ميرتازابين وتيزانيدين للاستخدام في اضطرابات الألم
ZA202102392B (en) Medicament for therapeutic treatment and/or improvement of sepsis accompanied by coagulopathy
NZ764072A (en) Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
UA115063U (xx) Спосіб лікування собак із больовим синдромом при панкреатиті